as of 08-21-2026 4:00pm EST
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 12.5M | IPO Year: | 2018 |
| Target Price: | $7.00 | AVG Volume (30 days): | 128.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | 94.50 |
| 52 Week Low/High: | $1.00 - $5.50 | Next Earning Date: | 05-13-2026 |
| Revenue: | $12,000,735 | Revenue Growth: | 26.26% |
| Revenue Growth (this year): | 14.99% | Revenue Growth (next year): | 34.73% |
| P/E Ratio: | -0.86 | Index: | N/A |
| Free Cash Flow: | -16345000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Interim Chief Executive
Avg Cost/Share
$1.22
Shares
4,000
Total Value
$4,860.00
Owned After
4,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Luderer Albert | BNGO | Interim Chief Executive | Aug 21, 2026 | Buy | $1.22 | 4,000 | $4,860.00 | 4,000 |
SEC 8-K filings with transcript text
Aug 10, 2026 · 100% conf.
1D
+1.90%
$1.18
5D
+13.82%
$1.32
20D
+18.11%
$1.37
2 bngo-ex99_1.htm
Exhibit 99.1
Bionano Reports Second Quarter 2026 Results and Provides a Business Update
Conference call today, August 10, 2026, at 4:30 PM ET
SAN DIEGO, August 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2026.
“Our second quarter results reflect a strong vote of confidence from our routine use customer community and the accelerating global adoption of optical genome mapping (OGM),” commented Al Luderer, Ph.D., chairman and interim chief executive officer of Bionano. “The evidence base supporting OGM continued to expand across a broad range of research areas, reflected by the year-over-year increase in OGM studies presented at major genetics conferences. All the while, growth in our consumable sales has been primarily driven by increased clinical adoption; this adoption, along with increased utilization at existing and new clinical sites, will continue to be the foundation of our growth. We were also pleased to welcome back Dr. Alex Hastie, one of the original architects of our technology, as Chief Scientific Officer. Equally important, we completed the full retirement of our outstanding secured convertible debentures during the quarter, a significant milestone that simplifies our financial profile and provides greater flexibility as we continue to grow adoption of OGM.”
Q2 2026 Financial Results
For the three-month period ended June 30, 2026, as compared to the same period of 2025:
• Reported total revenue of $8.2 million, representing an increase of 21% from $6.7 million in the second quarter of 2025.
• Consumables revenue was $4.3 million, representing an increase of 31%, as compared to the second quarter of 2025.
• Sold 9,219 nanochannel array flow cells in the second quarter of 2026, representing an increase of 27 % over the 7,233 flow cells sold in the second quarter of 2025.
• Generated gross margin of 53%, as compared to 52% for the second quarter of 2025.
• Operating expenses increased by 2% to $11.5 million while adjusted operating expense1 decreased by 2%to $8.7 million.
Recent Business Highlights:
• New publication from Johns Hopkins and MD Anderson Cancer Center in the American Journal of Hematology demonstrating that OGM can significantly outperform traditional analytical methods for detection of structural variations and chromosomal abnormalities in multiple myeloma.
• Announced the largest OGM study of T-cell acute lymphoblastic leukemia to date, published in Modern Pathology, showing OGM detected genomic abnormalities in 97.8% of cases compared to 55% by conventional karyotyping.
• Announced the full retirement of all outstanding Senior Secured Convertible Debentures, eliminating outstanding secured debt obligations and releasing all liens on the Company’s assets.
• Announced multiple 2026 publications describing the unique utility of OGM in reproductive health and prenatal genetic disorders, with 13 studies analyzing 730 subjects published to date.
• Announced a 67% year-over-year increase in studies featuring OGM at the 2026 European Society of Human Genetics (ESHG) conference, with authorship spanning 17 countries, up from 12 in 2025.
1”Adjusted gross margin” and “adjusted operating expense” are non-GAAP financial measures. Please refer to the section titled “Adjusted Financial Measures” below for a description of the adjusted financial measures used herein. Reconciliations of adjusted financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this release.
• Announced the appointment of Alex Hastie, Ph.D., a foundational figure in Bionano’s scientific evolution, as Chief Scientific Officer.
2026 Outlook
We anticipate the following results for Q3 and the full year 2026:
• Q3 2026 revenue guidance in the range of $8.2 to $8.6 million.
• Full year 2026 revenue guidance in the range of $31 to $33 million.
Webcast Details
Webcast Details
Date:
Monday, August 10, 2026
Time:
4:30 p.m. Eastern Time
Participant Registration:
https://register-conf.media-server.com/register/BI94bcb9b989ac4cbf942ab6d5dd8738fe
Webcast:
https://edge.media-server.com/mmc/p/ui7wih6m/
Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading
May 13, 2026 · 100% conf.
1D
-3.72%
$1.20
Act: -4.80%
5D
-15.11%
$1.06
Act: -0.80%
20D
+138.94%
$2.99
Act: -4.80%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784722696.738ede4
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Mar 23, 2026 · 100% conf.
1D
-2.90%
$1.54
Act: -0.63%
5D
-15.09%
$1.35
Act: -9.43%
20D
+163.27%
$4.19
Act: -26.42%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784722699.7390bcb
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how BNGO stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BNGO Bionano Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.